OTI1H1-Defined MAGEA3-Directed Immunoreactivity and Survival in Pancreatic Ductal Adenocarcinoma: A Single-Center Study

Background/Objectives: Melanoma-associated antigen A3 (MAGEA3) is a cancer–testis antigen with potential biological and prognostic relevance in pancreatic ductal adenocarcinoma (PDAC). This study evaluated the association between OTI1H1-defined MAGEA3-directed immunoreactivity and clinicopathological characteristics and overall survival after pancreatic resection for PDAC.

Methods

This retrospective cohort included 76 patients with histologically confirmed PDAC. Patients who died within 30 postoperative days were excluded, and all tumors were retrospectively restaged according to the eighth edition of the AJCC TNM classification. Immunohistochemical staining was assessed using the mouse monoclonal anti-MAGE3 antibody clone OTI1H1 (ab140678, Abcam) by a single experienced pathologist blinded to clinical and outcome data. The percentage of immunoreactive tumor cells was retained as the principal exploratory quantitative measure; the prespecified <10% versus ≥10% classification was evaluated secondarily.